Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MindRank OK’d to Start US Trials of GLP-1 Candidate for Obesity and Diabetes

publication date: Dec 27, 2022

Hangzhou MindRank, an AI drug discovery company, was approved to start a US Phase I trial of its lead candidate, a glucagon-like peptide 1 receptor agonist , aimed at obesity and type 2 diabetes mellitus. MindRank plans to start a Phase I safety study in the first quarter of 2023. Using its proprietary AI drug discovery platform, Molecule Pro™, MindRank advanced MDR-001 to IND approval in 19 months. The company had to synthesize and test fewer than 100 chemical compounds before finding the preclinical candidate. It believes MDR-001 has best-in-class potential. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital